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Alpha-Synuclein (alpha-syn) is the major building block
of cytoplasmic inclusions in neurodegenerative disorders
named synucleinopathies, such as Parkinson's Disease
and multiple system atrophy (MSA). In MSA glial cyto-
plasmic inclusions (GCIs) originating in oligodendro-
cytes are prominent. During disease progression a shift in
alpha-syn solubility is observable, and oxidative modifi-
cation of alpha-syn has been linked to neurodegeneration
and fibril formation. Furthermore, an overlap of patho-
logical features of patients with tauopathies, e.g. fronto-
temporal dementias including Pick's disease and
progressive supranuclear palsy, has been reported, and it
has been argued that alpha-syn aggregation can induce the
fibrillization of tau.
To investigate the possible involvement of oxidative stress
in alpha-syn aggregate formation, we have engineered
OLN-t40 cells, a cell line with oligodendroglial character-
istics stably expressing the longest human isoform of the
microtubule associated protein Tau, to express wild type
alpha-syn or the A53T alpha-syn mutation. alpha-Syn
expression in both cell lines caused the appearance of
small punctuated alpha-syn aggregates, which did not
stain with thioflavine S, and were negative for tau and
heat shock proteins (HSPs). These aggregates were more
abundant in cells expressing the A53T alpha-syn mutation
and therefore OLN-t40-A53T cells were used in the fol-
lowing studies.
Oxidative stress, exerted by hydrogen peroxide, led to an
enlargement of the cytoplasmic protein inclusions, and to
the recruitment of Tau and HSP90, HSP70 and alphaB-
crystallin to the inclusions. However, oxidative stress did
not cause an increase in alpha-syn in the detergent insol-
uble fraction, possibly indicating that alpha-syn did not
further accumulate and was of prefibrillary nature, and
still degradable by the proteasomal system. To test this,
cells were treated with hydrogen peroxide first and then
with the proteasomal inhibitor MG-132. The results show
that oxidative stress followed by proteasomal inhibition
leads to a decrease in alpha-syn solubility and to the
occurence of larger thioflavine S-positive inclusions,
which was not seen either after oxidative stress or protea-
somal inhibition alone.
In summary, oxidative modification in combination with
proteasomal impairment, contributes to alterations in the
solubility of alpha-syn, and leads to the formation of
inclusions resembling GCIs. HSPs were upregulated and
together with tau recruited to the GCIs, possibly further
contributing to the formation of degenerative inclusions.
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